Sanofi - ADR (SNY): Price and Financial Metrics


Sanofi - ADR (SNY): $54.40

1.34 (+2.53%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

SNY POWR Grades


  • Value is the dimension where SNY ranks best; there it ranks ahead of 91.28% of US stocks.
  • The strongest trend for SNY is in Stability, which has been heading down over the past 179 days.
  • SNY ranks lowest in Momentum; there it ranks in the 8th percentile.

SNY Stock Summary

  • With a market capitalization of $129,944,581,874, Sanofi has a greater market value than 98.13% of US stocks.
  • In terms of twelve month growth in earnings before interest and taxes, Sanofi is reporting a growth rate of 151.38%; that's higher than 86.84% of US stocks.
  • In terms of volatility of its share price, SNY is more volatile than only 2.24% of stocks we're observing.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Sanofi are GSK, DE, IBM, CAT, and AMGN.
  • SNY's SEC filings can be seen here. And to visit Sanofi's official web site, go to www.sanofi.com.

SNY Stock Price Chart Interactive Chart >

Price chart for SNY

SNY Price/Volume Stats

Current price $54.40 52-week high $58.10
Prev. close $53.06 52-week low $46.92
Day low $53.78 Volume 1,938,600
Day high $54.57 Avg. volume 2,047,561
50-day MA $53.03 Dividend yield 2.37%
200-day MA $51.05 Market Cap 137.48B

Sanofi - ADR (SNY) Company Bio


Sanofi researches, develops, manufactures, and markets various therapeutic solutions. The company operates in three segments: Pharmaceuticals, Vaccines, and Animal Health. The company was founded in 1973 and is based in Paris, France.


SNY Latest News Stream


Event/Time News Detail
Loading, please wait...

SNY Latest Social Stream


Loading social stream, please wait...

View Full SNY Social Stream

Latest SNY News From Around the Web

Below are the latest news stories about Sanofi that investors may wish to consider to help them evaluate SNY as an investment opportunity.

Drugmakers Seek Emergency Authorization For New COVID Vaccine

Watch Video European drugmakers Sanofi and Glaxosmithkline (GSK) released data showing their COVID vaccine is 100% effective at keeping patients out of the hospital. It has not been independently scientifically reviewed. Drugmakers Sanofi and GlaxoSmithKline have asked the Food and Drug Administration for emergency use authorization of their vaccine. "We are confident that this vaccine can play an important role as we continue to address this pandemic and prepare for the post-pandemic period," Roger Connor, president of GSK, said in a statement. Sanofi''s and GSK''s vaccine is based on a more conventional protein-based vaccine technology. It''s a recombinant protein vaccine, which means it recombines different segments of DNA. This uses DNA from the SARS-COV-2 spike protein, which COVID...

Newsy | February 25, 2022

Canada Approves First Plant-Based COVID-19 Vaccine

As Sanofi SA (NASDAQ: SNY ) and GlaxoSmithKline Plc''s (NYSE: GSK ) COVID-19 vaccine finally heads to regulators, another shot using GSK''s pandemic adjuvant has won its first global approval . Mitsubishi Tanabe Pharma Corporation -backed Medicago''s recombinant COVID-19 vaccine, dubbed Covifenz, has snagged a green light in Canada in individuals 18 to 64 years of age. The vaccine uses a plant-based virus-like particles technology to mimic … Full story available on Benzinga.com

Benzinga | February 25, 2022

Pharma Stock Roundup: GSK, SNY Face Pipeline Setbacks, AZN Cancer Study Meets Goals

Glaxo (GSK) and Sanofi (SNY) announce pipeline setbacks. AstraZeneca's (AZN) HER2-low metastatic breast cancer study on Enhertu succeeds.

Yahoo | February 25, 2022

France''s Sanofi to seek Covid vaccine approval after months of delays

French pharmaceuticals giant Sanofi has said that its Covid-19 vaccine, developed with Britain''s GlaxoSmithKline, had delivered positive results after nearly a year of setbacks that left it lagging far behind its rivals.

Radio France Internationale | February 24, 2022

Sanofi, GSK say vaccine shows 100% efficacy against hospitalization due to severe disease: Live COVID updates

Sanofi and GSK seek approval for a vaccine they say shows 100% efficacy against hospitalization due to severe disease in human trials. COVID updates.

Azcentral | February 24, 2022

Read More 'SNY' Stories Here

SNY Price Returns

1-mo -0.24%
3-mo 6.13%
6-mo 10.05%
1-year 3.11%
3-year 42.34%
5-year 31.28%
YTD 11.21%
2021 5.87%
2020 -0.83%
2019 23.73%
2018 4.20%
2017 8.73%

SNY Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full SNY Dividend History

Continue Researching SNY

Want to see what other sources are saying about Sanofi's financials and stock price? Try the links below:

Sanofi (SNY) Stock Price | Nasdaq
Sanofi (SNY) Stock Quote, History and News - Yahoo Finance
Sanofi (SNY) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8846 seconds.